<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03269201</url>
  </required_header>
  <id_info>
    <org_study_id>4408-17</org_study_id>
    <nct_id>NCT03269201</nct_id>
  </id_info>
  <brief_title>Brain Network Activation in Patients With Movement Disorders</brief_title>
  <acronym>BNA-MDi</acronym>
  <official_title>Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals in Patients With Movement Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The diagnosis and management of movement disorders, such as Parkinson's disease (PD),&#xD;
      parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure&#xD;
      hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and&#xD;
      monitoring tools with high sensitivity and specificity. A cornerstone in research of&#xD;
      neurological disorders manifesting as MDi is the investigation of neurophysiological changes&#xD;
      as potential biomarkers that could help in diagnosis, monitoring disease progression and&#xD;
      response to therapies. Such a neuro-marker that would overcome the major disadvantages of&#xD;
      clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating&#xD;
      scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and&#xD;
      others), including low test-retest repeatability and subjective judgment of different raters,&#xD;
      would have real impact on disease diagnosis and choice of interventions and monitoring of&#xD;
      effects of novel therapeutics, including disease modifying therapies.&#xD;
&#xD;
      To address this, ElMindA has developed over the last decade a non-invasive, low-cost&#xD;
      technology named Brain Network Activation (BNA), which is a new imaging approach that can&#xD;
      detect changes in brain activity and functional connectivity. Results from proof-of concept&#xD;
      studies on PD patients have demonstrated that: 1) PD patients exhibited a significant&#xD;
      decrease in BNA scores relatively to healthy controls; 2) notable changes in functional&#xD;
      network activity in correlation with different dopamine-agonist doses; 3) significant&#xD;
      correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from&#xD;
      healthy controls&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The primary aim of the current project is to assess the utility of the BNA as a&#xD;
      quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above&#xD;
      most common MDi in man.&#xD;
&#xD;
      The secondary aim is to find predictive bio-types (electrophysiological fingerprint) of the&#xD;
      above MDi and within these disorders identifying patients with high likelihood of developing:&#xD;
      1) psychiatric complications such as dopaminergic medication induced-impulse control disorder&#xD;
      (ICD) for PD; 2) Depression; 3) Gait and balance Impairment; or 4) Cognitive deterioration,&#xD;
      including (PD-MCI) or PD-dementia (PDD).&#xD;
&#xD;
      The technology: BNA technology is based on non-invasive recordings of multi-channel EEG&#xD;
      event-related potentials (ERPs), and a comprehensive multi-dimensional analysis of such&#xD;
      recordings, aimed at understanding and visualizing the network complexity (or Brain Networks&#xD;
      Activation patterns) of brain function. BNA takes cognitive ERPs, a direct measure of neural&#xD;
      activity associated with cognitive functions, to a new frontier, unparalleled by EEG, QEEG or&#xD;
      ERP alone or by any other anatomic and functional brain imaging and evaluation tools. The BNA&#xD;
      algorithms use innovative sets of signal processing, pattern recognition and machine learning&#xD;
      techniques to seek and map activated neural pathways while patients are engaged in a&#xD;
      cognitive task. The resulting BNA network patterns can aid clinicians with profiling of&#xD;
      changes in functionality and/or dysfunctionality. BNA received an FDA clearance and a CE mark&#xD;
      approval during 2014, and is commercially available in the US, with more than 20 active&#xD;
      clinical and research sites focusing on numerous neurological and neuropsychological&#xD;
      disorders. More than 30,000 data sets of functional brain networks of healthy subjects have&#xD;
      been already collected and may serve as normative data for comparison.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MDS-UPDRS part III score</measure>
    <time_frame>3 years</time_frame>
    <description>Motor severity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Cooperative Ataxia Rating Scale</measure>
    <time_frame>3 years</time_frame>
    <description>scale for ataxia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TETRAS</measure>
    <time_frame>3 years</time_frame>
    <description>The Essential Tremor Rating Assessment Scale (TETRAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDS-UPDRS total score</measure>
    <time_frame>3 years</time_frame>
    <description>General measure for PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MoCA Montreal - Cognitive Assessment</measure>
    <time_frame>3 years</time_frame>
    <description>Cognitive Assessment</description>
  </secondary_outcome>
  <number_of_groups>9</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Essential Tremor</condition>
  <condition>Dystonia</condition>
  <condition>Normal Pressure Hydrocephalus</condition>
  <condition>Cerebellar Ataxia</condition>
  <condition>Multiple System Atrophy</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <condition>Corticobasal Degeneration</condition>
  <condition>Dementia With Lewy Bodies</condition>
  <arm_group>
    <arm_group_label>Parkinson;s Disease</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essential tremor</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple system atrophy</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Pressure Hydrocephalus</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DYSTONIA-focal, generalized and others</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia&#xD;
.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cerebellar ataxia</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressive supranuclear palsy</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticobasal degeneration</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia with Lewy Bodies</arm_group_label>
    <description>Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of 300 patients with MDs:&#xD;
&#xD;
        Idiopathic PD , ET, PPS, NPH, dystonia and CAs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For PD: Idiopathic PD patients (according to the UK PD Society brain bank clinical&#xD;
             diagnostic criteria (bradykinesia plus at least one other cardinal feature of PD, no&#xD;
             atypical features or secondary cause).&#xD;
&#xD;
          -  For ET: bilateral, largely symmetrical postural or kinetic tremor involving hand and&#xD;
             forearms that is visible and persistent. Additional or isolated tremor of the head may&#xD;
             occur but in the absence of abnormal posturing.&#xD;
&#xD;
          -  For Parkinson plus syndrome: multiple system atrophy (MSA), progressive supranuclear&#xD;
             palsy (PSP), corticobasal degeneration (CBD) and dementia with Lewy bodies (DLB).&#xD;
&#xD;
          -  For NPH: patients exhibiting some or all components of the clinical triad consisting&#xD;
             of gait disturbance, urinary control disturbance and cognitive impairment as well as&#xD;
             proof of enlarged ventricular system or hydrocephalus by cranial CT or MRI scans.&#xD;
&#xD;
          -  For Dystonia: patients exhibiting a movement disorder syndrome in which sustained or&#xD;
             repetitive muscle contractions result in twisting and repetitive movements or abnormal&#xD;
             fixed postures. The movements may resemble a tremor. Patients included will be those&#xD;
             with either idiopathic, toxic or hereditary mechanism.&#xD;
&#xD;
          -  For Cerebellar ataxia: patients exhibiting impairment of coordination and balance as&#xD;
             part of an ataxic cerebellar syndrome which is caused by degeneration of the&#xD;
             cerebellum and its afferent and efferent connections due to various etiologies, such&#xD;
             as genetic or sporadic neurodegenerative processes or others.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the investigator's opinion, any unstable or clinically significant condition that&#xD;
             would impair the participants' ability to comply with study requirements.&#xD;
&#xD;
          -  Patients with significant psychiatric symptoms or history or treatment with&#xD;
             neuroleptics.&#xD;
&#xD;
          -  MMSE &lt;10&#xD;
&#xD;
          -  Currently with lice or open wounds on scalp.&#xD;
&#xD;
          -  Significant sensory deficits, e.g., deafness or blindness&#xD;
&#xD;
          -  Current drug abuse or alcoholism.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Movement Disorders Clinic, Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Reches A, Nir RR, Shram MJ, Dickman D, Laufer I, Shani-Hershkovich R, Stern Y, Weiss M, Yarnitsky D, Geva AB. A novel electroencephalography-based tool for objective assessment of network dynamics activated by nociceptive stimuli. Eur J Pain. 2016 Feb;20(2):250-62. doi: 10.1002/ejp.716. Epub 2015 May 11.</citation>
    <PMID>25960035</PMID>
  </reference>
  <reference>
    <citation>Reches A, Levy-Cooperman N, Laufer I, Shani-Hershkovitch R, Ziv K, Kerem D, Gal N, Stern Y, Cukierman G, Romach MK, Sellers EM, Geva AB. Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory. J Mol Neurosci. 2014 Sep;54(1):59-70. doi: 10.1007/s12031-014-0250-6. Epub 2014 Feb 18.</citation>
    <PMID>24535560</PMID>
  </reference>
  <reference>
    <citation>Reches A, Laufer I, Ziv K, Cukierman G, McEvoy K, Ettinger M, Knight RT, Gazzaley A, Geva AB. Network dynamics predict improvement in working memory performance following donepezil administration in healthy young adults. Neuroimage. 2014 Mar;88:228-41. doi: 10.1016/j.neuroimage.2013.11.020. Epub 2013 Nov 21.</citation>
    <PMID>24269569</PMID>
  </reference>
  <reference>
    <citation>Sang L, Zhang J, Wang L, Zhang J, Zhang Y, Li P, Wang J, Qiu M. Alteration of Brain Functional Networks in Early-Stage Parkinson's Disease: A Resting-State fMRI Study. PLoS One. 2015 Oct 30;10(10):e0141815. doi: 10.1371/journal.pone.0141815. eCollection 2015.</citation>
    <PMID>26517128</PMID>
  </reference>
  <reference>
    <citation>Gao LL, Wu T. The study of brain functional connectivity in Parkinson's disease. Transl Neurodegener. 2016 Oct 28;5:18. doi: 10.1186/s40035-016-0066-0. eCollection 2016.</citation>
    <PMID>27800157</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Sharon Hassin</investigator_full_name>
    <investigator_title>Director, Movement Disorders Institute.</investigator_title>
  </responsible_party>
  <keyword>parkinsonism</keyword>
  <keyword>ataxia</keyword>
  <keyword>tremor</keyword>
  <keyword>dystonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Movement Disorders</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
    <mesh_term>Hydrocephalus</mesh_term>
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Lewy Body Disease</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Hydrocephalus, Normal Pressure</mesh_term>
    <mesh_term>Corticobasal Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03269201
org study id: 4408-17
nct id: NCT03269201
lead sponsor: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The diagnosis and management of movement disorders, such as Parkinson's disease (PD),
      parkinson-plus syndromes (PPS), dystonia, essential tremor (ET), normal pressure
      hydrocephalus (NPH) and others is challenging given the lack of objective diagnostic and
      monitoring tools with high sensitivity and specificity. A cornerstone in research of
      neurological disorders manifesting as MDi is the investigation of neurophysiological changes
      as potential biomarkers that could help in diagnosis, monitoring disease progression and
      response to therapies. Such a neuro-marker that would overcome the major disadvantages of
      clinical questionnaires and rating scales (such as the Unified Parkinson's disease rating
      scale -UPDRS, for PD, The Essential Tremor Rating Assessment Scale -TETRAS, for ET and
      others), including low test-retest repeatability and subjective judgment of different raters,
      would have real impact on disease diagnosis and choice of interventions and monitoring of
      effects of novel therapeutics, including disease modifying therapies.

      To address this, ElMindA has developed over the last decade a non-invasive, low-cost
      technology named Brain Network Activation (BNA), which is a new imaging approach that can
      detect changes in brain activity and functional connectivity. Results from proof-of concept
      studies on PD patients have demonstrated that: 1) PD patients exhibited a significant
      decrease in BNA scores relatively to healthy controls; 2) notable changes in functional
      network activity in correlation with different dopamine-agonist doses; 3) significant
      correlation between BNA score and the UPDRS). 4) BNA could also differentiate early PD from
      healthy controls
Objective: The primary aim of the current project is to assess the utility of the BNA as a
      quantitative, objective, neurophysiological marker for diagnosis and monitoring of the above
      most common MDi in man.

      The secondary aim is to find predictive bio-types (electrophysiological fingerprint) of the
      above MDi and within these disorders identifying patients with high likelihood of developing:
      1) psychiatric complications such as dopaminergic medication induced-impulse control disorder
      (ICD) for PD; 2) Depression; 3) Gait and balance Impairment; or 4) Cognitive deterioration,
      including (PD-MCI) or PD-dementia (PDD).

      The technology: BNA technology is based on non-invasive recordings of multi-channel EEG
      event-related potentials (ERPs), and a comprehensive multi-dimensional analysis of such
      recordings, aimed at understanding and visualizing the network complexity (or Brain Networks
      Activation patterns) of brain function. BNA takes cognitive ERPs, a direct measure of neural
      activity associated with cognitive functions, to a new frontier, unparalleled by EEG, QEEG or
      ERP alone or by any other anatomic and functional brain imaging and evaluation tools. The BNA
      algorithms use innovative sets of signal processing, pattern recognition and machine learning
      techniques to seek and map activated neural pathways while patients are engaged in a
      cognitive task. The resulting BNA network patterns can aid clinicians with profiling of
      changes in functionality and/or dysfunctionality. BNA received an FDA clearance and a CE mark
      approval during 2014, and is commercially available in the US, with more than 20 active
      clinical and research sites focusing on numerous neurological and neuropsychological
      disorders. More than 30,000 data sets of functional brain networks of healthy subjects have
      been already collected and may serve as normative data for comparison.
observational model: Case-Only
time perspective: Cross-Sectional
measure: MDS-UPDRS part III score
time frame: 3 years
description: Motor severity
measure: International Cooperative Ataxia Rating Scale
time frame: 3 years
description: scale for ataxia
measure: TETRAS
time frame: 3 years
description: The Essential Tremor Rating Assessment Scale (TETRAS)
measure: MDS-UPDRS total score
time frame: 3 years
description: General measure for PD
measure: MoCA Montreal - Cognitive Assessment
time frame: 3 years
description: Cognitive Assessment
arm group label: Parkinson;s Disease
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
arm group label: Essential tremor
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis.Additionally patients will be rated using mmse/ MoCA, Verbal Fluency, essential tremor rating assessment scale (TETRAS) clinical rating scale for tremor (CRST).SF-EMG and KinesiaOne and motion sensor assessment writing and drawing on digitizer, for tremor.
arm group label: Multiple system atrophy
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
arm group label: Normal Pressure Hydrocephalus
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - TIMED UP AND GO TASK (INSTRUMENTAL)
arm group label: DYSTONIA-focal, generalized and others
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.Fahn-Marsden Evaluation Scale for Dystonia
.SF-EMG and KinesiaOne and motion sensor assessment , writing and drawing on digitizer,for dystonia
arm group label: Cerebellar ataxia
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency,Scale for the assessment and rating of ataxia (SARA), International Cooperative Ataxia Rating Scale . TIMED UP AND GO TASK (INSTRUMENTAL)
arm group label: Progressive supranuclear palsy
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
arm group label: Corticobasal degeneration
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
arm group label: Dementia with Lewy Bodies
description: Patients will undergo EEG recordings at rest and while performing the set of motor and cognitive tasks and BNA analysis. Additionally patients will be rated using MoCA, FAB, Verbal Fluency, - Beck Depression Inventory, PDQ-39, PD sleep scale (PDSS), MDS-UPDRS.SF-EMG and KinesiaOne and motion sensor assessment for tremor.
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: 85 Years
healthy volunteers: No
facility: 
country: Israel
citation: Reches A, Nir RR, Shram MJ, Dickman D, Laufer I, Shani-Hershkovich R, Stern Y, Weiss M, Yarnitsky D, Geva AB. A novel electroencephalography-based tool for objective assessment of network dynamics activated by nociceptive stimuli. Eur J Pain. 2016 Feb;20(2):250-62. doi: 10.1002/ejp.716. Epub 2015 May 11.
PMID: 25960035
citation: Reches A, Levy-Cooperman N, Laufer I, Shani-Hershkovitch R, Ziv K, Kerem D, Gal N, Stern Y, Cukierman G, Romach MK, Sellers EM, Geva AB. Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory. J Mol Neurosci. 2014 Sep;54(1):59-70. doi: 10.1007/s12031-014-0250-6. Epub 2014 Feb 18.
PMID: 24535560
citation: Reches A, Laufer I, Ziv K, Cukierman G, McEvoy K, Ettinger M, Knight RT, Gazzaley A, Geva AB. Network dynamics predict improvement in working memory performance following donepezil administration in healthy young adults. Neuroimage. 2014 Mar;88:228-41. doi: 10.1016/j.neuroimage.2013.11.020. Epub 2013 Nov 21.
PMID: 24269569
citation: Sang L, Zhang J, Wang L, Zhang J, Zhang Y, Li P, Wang J, Qiu M. Alteration of Brain Functional Networks in Early-Stage Parkinson's Disease: A Resting-State fMRI Study. PLoS One. 2015 Oct 30;10(10):e0141815. doi: 10.1371/journal.pone.0141815. eCollection 2015.
PMID: 26517128
citation: Gao LL, Wu T. The study of brain functional connectivity in Parkinson's disease. Transl Neurodegener. 2016 Oct 28;5:18. doi: 10.1186/s40035-016-0066-0. eCollection 2016.
PMID: 27800157
responsible party type: Principal Investigator
investigator affiliation: Sheba Medical Center
investigator full name: Dr. Sharon Hassin
investigator title: Director, Movement Disorders Institute.
mesh term: Parkinson Disease
mesh term: Ataxia
mesh term: Dystonia
mesh term: Tremor
mesh term: Movement Disorders
mesh term: Essential Tremor
mesh term: Hydrocephalus
mesh term: Multiple System Atrophy
mesh term: Shy-Drager Syndrome
mesh term: Supranuclear Palsy, Progressive
mesh term: Lewy Body Disease
mesh term: Cerebellar Ataxia
mesh term: Hydrocephalus, Normal Pressure
mesh term: Corticobasal Degeneration